Effects of Allopurinol in Duchenne's Muscular Dystrophy

Increased catalase expression improves muscle function inmdxmice

“…While antioxidant use has been largely successful in rodent models, it has consistently failed in clinical trials (Mendell & Wiechers, 1979; Stern et al 1982; Tamari et al 1982; Hunter et al 1983; Gamstorp et al 1986; Fenichel et al 1988). These failures may be due to insufficient dosing and/or poor matching of antioxidant and oxidant, both in terms of chemical interaction and intracellular localization.…”

“…This early oxidative stress may lead to the initial necrotic bout seen in mdx skeletal muscle and may be an early causative event in initiation and progression of human DMD. While the free radical component of the disease has been well documented, numerous clinical trials using antioxidants have failed to attenuate disease symptoms (Mendell & Wiechers, 1979; Stern et al 1982; Tamari et al 1982; Hunter et al 1983; Gamstorp et al 1986; Fenichel et al 1988). This may indicate that oxidant damage has a role early in disease initiation or progression, but not later.…”

Increased catalase expression improves muscle function inmdxmice

“…While antioxidant use has been largely successful in rodent models, it has consistently failed in clinical trials (Mendell & Wiechers, 1979; Stern et al 1982; Tamari et al 1982; Hunter et al 1983; Gamstorp et al 1986; Fenichel et al 1988). These failures may be due to insufficient dosing and/or poor matching of antioxidant and oxidant, both in terms of chemical interaction and intracellular localization.…”

“…This early oxidative stress may lead to the initial necrotic bout seen in mdx skeletal muscle and may be an early causative event in initiation and progression of human DMD. While the free radical component of the disease has been well documented, numerous clinical trials using antioxidants have failed to attenuate disease symptoms (Mendell & Wiechers, 1979; Stern et al 1982; Tamari et al 1982; Hunter et al 1983; Gamstorp et al 1986; Fenichel et al 1988). This may indicate that oxidant damage has a role early in disease initiation or progression, but not later.…”

Metabogenic and Nutriceutical Approaches to Address Energy Dysregulation and Skeletal Muscle Wasting in Duchenne Muscular Dystrophy

“…To increase sample size, all 6 patients received allopurinol for a further 8 weeks to no avail, therefore the authors concluded allopurinol to have no therapeutic effect [ 209 ]. Similarly, following an 8 months 150 mg allopurinol supplementation in dystrophic boys aged 5 to 13, no clinical improvement, but rather, deterioration was observed in functional and strength tests [ 210 ] with comparable findings observed following two 3-month trials of 100 mg allopurinol [ 211 ].…”

“…The majority of studies that have deemed allopurinol therapy to be ineffective for DMD treatment noted a deterioration of muscle function during and following the supplementation period [ 197 , 210 , 211 , 212 , 213 ]. This may be reflective of the age of participants in these trials and to what degree the disease had progressed, with the baseline measurements of these studies indicating that younger patients were able to perform better on functional tests and generally saw some sort of improvement from allopurinol treatment.…”

Stages of research and development of therapeutic approaches for Duchenne myodystrophy. Part I: the period before etiotropic approaches introduction

“…Bertorini и соавт. в 1985 г. сообщали об отсутствии положительного влияния на основные показатели и, в некоторых случаях, ухудшении функционального состояния мышц до и/или после окончания приема препарата [54][55][56][57][58][59]. Снижение уровня мочевой кислоты в крови без улучшения иных клинически значимых показателей продемонстрировали L.M.…”

Increased catalase expression improves muscle function inmdxmice

“…While antioxidant use has been largely successful in rodent models, it has consistently failed in clinical trials (Mendell & Wiechers, 1979; Stern et al 1982; Tamari et al 1982; Hunter et al 1983; Gamstorp et al 1986; Fenichel et al 1988). These failures may be due to insufficient dosing and/or poor matching of antioxidant and oxidant, both in terms of chemical interaction and intracellular localization.…”

“…This early oxidative stress may lead to the initial necrotic bout seen in mdx skeletal muscle and may be an early causative event in initiation and progression of human DMD. While the free radical component of the disease has been well documented, numerous clinical trials using antioxidants have failed to attenuate disease symptoms (Mendell & Wiechers, 1979; Stern et al 1982; Tamari et al 1982; Hunter et al 1983; Gamstorp et al 1986; Fenichel et al 1988). This may indicate that oxidant damage has a role early in disease initiation or progression, but not later.…”

Metabogenic and Nutriceutical Approaches to Address Energy Dysregulation and Skeletal Muscle Wasting in Duchenne Muscular Dystrophy

“…To increase sample size, all 6 patients received allopurinol for a further 8 weeks to no avail, therefore the authors concluded allopurinol to have no therapeutic effect [ 209 ]. Similarly, following an 8 months 150 mg allopurinol supplementation in dystrophic boys aged 5 to 13, no clinical improvement, but rather, deterioration was observed in functional and strength tests [ 210 ] with comparable findings observed following two 3-month trials of 100 mg allopurinol [ 211 ].…”

“…The majority of studies that have deemed allopurinol therapy to be ineffective for DMD treatment noted a deterioration of muscle function during and following the supplementation period [ 197 , 210 , 211 , 212 , 213 ]. This may be reflective of the age of participants in these trials and to what degree the disease had progressed, with the baseline measurements of these studies indicating that younger patients were able to perform better on functional tests and generally saw some sort of improvement from allopurinol treatment.…”

Stages of research and development of therapeutic approaches for Duchenne myodystrophy. Part I: the period before etiotropic approaches introduction

“…Bertorini и соавт. в 1985 г. сообщали об отсутствии положительного влияния на основные показатели и, в некоторых случаях, ухудшении функционального состояния мышц до и/или после окончания приема препарата [54][55][56][57][58][59]. Снижение уровня мочевой кислоты в крови без улучшения иных клинически значимых показателей продемонстрировали L.M.…”

Increased catalase expression improves muscle function inmdxmice

“…While antioxidant use has been largely successful in rodent models, it has consistently failed in clinical trials (Mendell & Wiechers, 1979; Stern et al 1982; Tamari et al 1982; Hunter et al 1983; Gamstorp et al 1986; Fenichel et al 1988). These failures may be due to insufficient dosing and/or poor matching of antioxidant and oxidant, both in terms of chemical interaction and intracellular localization.…”

“…This early oxidative stress may lead to the initial necrotic bout seen in mdx skeletal muscle and may be an early causative event in initiation and progression of human DMD. While the free radical component of the disease has been well documented, numerous clinical trials using antioxidants have failed to attenuate disease symptoms (Mendell & Wiechers, 1979; Stern et al 1982; Tamari et al 1982; Hunter et al 1983; Gamstorp et al 1986; Fenichel et al 1988). This may indicate that oxidant damage has a role early in disease initiation or progression, but not later.…”

Metabogenic and Nutriceutical Approaches to Address Energy Dysregulation and Skeletal Muscle Wasting in Duchenne Muscular Dystrophy

“…To increase sample size, all 6 patients received allopurinol for a further 8 weeks to no avail, therefore the authors concluded allopurinol to have no therapeutic effect [ 209 ]. Similarly, following an 8 months 150 mg allopurinol supplementation in dystrophic boys aged 5 to 13, no clinical improvement, but rather, deterioration was observed in functional and strength tests [ 210 ] with comparable findings observed following two 3-month trials of 100 mg allopurinol [ 211 ].…”

“…The majority of studies that have deemed allopurinol therapy to be ineffective for DMD treatment noted a deterioration of muscle function during and following the supplementation period [ 197 , 210 , 211 , 212 , 213 ]. This may be reflective of the age of participants in these trials and to what degree the disease had progressed, with the baseline measurements of these studies indicating that younger patients were able to perform better on functional tests and generally saw some sort of improvement from allopurinol treatment.…”

Stages of research and development of therapeutic approaches for Duchenne myodystrophy. Part I: the period before etiotropic approaches introduction

“…Bertorini и соавт. в 1985 г. сообщали об отсутствии положительного влияния на основные показатели и, в некоторых случаях, ухудшении функционального состояния мышц до и/или после окончания приема препарата [54][55][56][57][58][59]. Снижение уровня мочевой кислоты в крови без улучшения иных клинически значимых показателей продемонстрировали L.M.…”